News | May 26, 2025
Gland Pharma Q4 FY25 PAT falls to Rs. 186.5 Cr
R&D spend for Q4 was Rs. 50.3 crore, 4.9 per cent of Q4?revenue
R&D spend for Q4 was Rs. 50.3 crore, 4.9 per cent of Q4?revenue
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
For the full year FY25, net profit soared 12x to Rs 345 crore
Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa's Recombinant Human Albumin in Europe
3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion
Q4 FY25 PAT stood at Rs. 90.7 crore as compared to Rs.77.6 crore in Q4 FY24
EBITDA for the period rose by 23.2% to Rs. 3,797 million
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
Standalone profit from operations for the quarter were Rs. 162 crores
Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25
Subscribe To Our Newsletter & Stay Updated
